Display options
Cite
Kahale LA, Matar CF, Hakoum MB, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2021;12:CD006649doi: 10.1002/14651858.CD006649.pub8.
Kahale, L. A., Matar, C. F., Hakoum, M. B., Tsolakian, I. G., Yosuico, V. E., Terrenato, I., Sperati, F., Barba, M., Schünemann, H., & Akl, E. A. (2021). Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. The Cochrane database of systematic reviews, 12CD006649. https://doi.org/10.1002/14651858.CD006649.pub8
Kahale, Lara A, et al. "Anticoagulation for the initial treatment of venous thromboembolism in people with cancer." The Cochrane database of systematic reviews vol. 12 (2021): CD006649. doi: https://doi.org/10.1002/14651858.CD006649.pub8
Kahale LA, Matar CF, Hakoum MB, Tsolakian IG, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2021 Dec 08;12:CD006649. doi: 10.1002/14651858.CD006649.pub8. PMID: 34878173; PMCID: PMC8653422.
Copy Download .nbib Format: NLM
Share it on

Cochrane Database Syst Rev. 2021 Dec 08;12:CD006649. doi: 10.1002/14651858.CD006649.pub8.

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

The Cochrane database of systematic reviews

Lara A Kahale, Charbel F Matar, Maram B Hakoum, Ibrahim G Tsolakian, Victor Ed Yosuico, Irene Terrenato, Francesca Sperati, Maddalena Barba, Holger Schünemann, Elie A Akl

Affiliations

  1. Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
  2. Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
  3. Department of Family Medicine, Cornerstone Care Teaching Health Center, Mt. Morris, Pennsylvania, USA.
  4. Department of Obstetrics and Gynaecology, Univeristy of Toledo, Toledo, Ohio, USA.
  5. Buffalo Medical Group, Buffalo, New York, USA.
  6. Biostatistics-Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  7. Division of Medical Oncology 2 - Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  8. Departments of Health Research Methods, Evidence, and Impact and of Medicine, McMaster University, Hamilton, Canada.
  9. Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

PMID: 34878173 PMCID: PMC8653422 DOI: 10.1002/14651858.CD006649.pub8

Abstract

BACKGROUND: Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE.

OBJECTIVES: To compare the efficacy and safety of three types of parenteral anticoagulants (i.e. fixed-dose low molecular weight heparin (LMWH), adjusted-dose unfractionated heparin (UFH), and fondaparinux) for the initial treatment of VTE in people with cancer.

SEARCH METHODS: We performed a comprehensive search in the following major databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (via Ovid) and Embase (via Ovid). We also handsearched conference proceedings, checked references of included studies, and searched for ongoing studies. This update of the systematic review is based on the findings of a literature search conducted on 14 August 2021.

SELECTION CRITERIA: Randomised controlled trials (RCTs) assessing the benefits and harms of LMWH, UFH, and fondaparinux in people with cancer and objectively confirmed VTE.

DATA COLLECTION AND ANALYSIS: Using a standardised form, we extracted data - in duplicate - on study design, participants, interventions, outcomes of interest, and risk of bias. Outcomes of interest included all-cause mortality, symptomatic VTE, major bleeding, minor bleeding, postphlebitic syndrome, quality of life, and thrombocytopenia. We assessed the certainty of evidence for each outcome using the GRADE approach.

MAIN RESULTS: Of 11,484 identified citations, 3073 were unique citations and 15 RCTs fulfilled the eligibility criteria, none of which were identified in the latest search. These trials enrolled 1615 participants with cancer and VTE: 13 compared LMWH with UFH; one compared fondaparinux with UFH and LMWH; and one compared dalteparin with tinzaparin, two different types of low molecular weight heparin. The meta-analyses showed that LMWH may reduce mortality at three months compared to UFH (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.40 to 1.10; risk difference (RD) 57 fewer per 1000, 95% CI 101 fewer to 17 more; low certainty evidence) and may reduce VTE recurrence slightly (RR 0.69, 95% CI 0.27 to 1.76; RD 30 fewer per 1000, 95% CI 70 fewer to 73 more; low certainty evidence). There were no data available for bleeding outcomes, postphlebitic syndrome, quality of life, or thrombocytopenia. The study comparing fondaparinux with heparin (UFH or LMWH) found that fondaparinux may increase mortality at three months (RR 1.25, 95% CI 0.86 to 1.81; RD 43 more per 1000, 95% CI 24 fewer to 139 more; low certainty evidence), may result in little to no difference in recurrent VTE (RR 0.93, 95% CI 0.56 to 1.54; RD 8 fewer per 1000, 95% CI 52 fewer to 63 more; low certainty evidence), may result in little to no difference in major bleeding (RR 0.82, 95% CI 0.40 to 1.66; RD 12 fewer per 1000, 95% CI 40 fewer to 44 more; low certainty evidence), and probably increases minor bleeding (RR 1.53, 95% CI 0.88 to 2.66; RD 42 more per 1000, 95% CI 10 fewer to 132 more; moderate certainty evidence). There were no data available for postphlebitic syndrome, quality of life, or thrombocytopenia. The study comparing dalteparin with tinzaparin found that dalteparin may reduce mortality slightly (RR 0.86, 95% CI 0.43 to 1.73; RD 33 fewer per 1000, 95% CI 135 fewer to 173 more; low certainty evidence), may reduce recurrent VTE (RR 0.44, 95% CI 0.09 to 2.16; RD 47 fewer per 1000, 95% CI 77 fewer to 98 more; low certainty evidence), may increase major bleeding slightly (RR 2.19, 95% CI 0.20 to 23.42; RD 20 more per 1000, 95% CI 14 fewer to 380 more; low certainty evidence), and may reduce minor bleeding slightly (RR 0.82, 95% CI 0.30 to 2.21; RD 24 fewer per 1000, 95% CI 95 fewer to 164 more; low certainty evidence). There were no data available for postphlebitic syndrome, quality of life, or thrombocytopenia.

AUTHORS' CONCLUSIONS: Low molecular weight heparin (LMWH) is probably superior to UFH in the initial treatment of VTE in people with cancer. Additional trials focusing on patient-important outcomes will further inform the questions addressed in this review. The decision for a person with cancer to start LMWH therapy should balance the benefits and harms and consider the person's values and preferences.

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

References

  1. N Engl J Med. 1981 Jul 16;305(3):170 - PubMed
  2. Intern Emerg Med. 2008 Jun;3(2):117-22 - PubMed
  3. Eur J Cardiothorac Surg. 2003 Oct;24(4):580-7 - PubMed
  4. J Vasc Surg. 2000 Sep;32(3):537-43 - PubMed
  5. Thromb Haemost. 2017 Jan 26;117(2):219-230 - PubMed
  6. Lancet Haematol. 2016 Aug;3(8):e379-87 - PubMed
  7. Thromb Res. 2011 Nov;128(5):417-21 - PubMed
  8. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  9. Thromb Haemost. 1993 Jul 1;70(1):204-7 - PubMed
  10. Surgery. 1969 Jun;65(6):894-7 - PubMed
  11. Thromb Haemost. 2011 Jun;105(6):981-8 - PubMed
  12. Arch Intern Med. 2005 Apr 11;165(7):733-8 - PubMed
  13. Zhonghua Zhong Liu Za Zhi. 2014 Jan;36(1):39-42 - PubMed
  14. J Thromb Haemost. 2015 Dec;13(12):2187-91 - PubMed
  15. Blood Coagul Fibrinolysis. 2003 Jun;14(4):341-6 - PubMed
  16. Arch Intern Med. 2004 May 24;164(10):1077-83 - PubMed
  17. Ann Oncol. 2005 May;16 Suppl 4:iv136-139 - PubMed
  18. Haemostasis. 1990;20 Suppl 1:205-19 - PubMed
  19. J Clin Epidemiol. 2016 Aug;76:147-54 - PubMed
  20. Eur J Clin Pharmacol. 1990;39(2):107-12 - PubMed
  21. Ann Ital Med Int. 1988 Jul-Sep;3(3):213-9 - PubMed
  22. Lancet. 1992 Feb 22;339(8791):441-5 - PubMed
  23. Int J Urol. 2016 Nov;23(11):923-928 - PubMed
  24. Lancet Haematol. 2014 Oct;1(1):e37-46 - PubMed
  25. Thromb Haemost. 1996 Aug;76(2):195-9 - PubMed
  26. Urology. 1992 Apr;39(4):309-13 - PubMed
  27. Chest. 2008 Jun;133(6 Suppl):141S-159S - PubMed
  28. J Clin Oncol. 2005 Oct 1;23(28):7248 - PubMed
  29. Vox Sang. 2002 Aug;83 Suppl 1:383-6 - PubMed
  30. N Engl J Med. 1998 Jul 9;339(2):80-5 - PubMed
  31. PLoS One. 2012;7(11):e49163 - PubMed
  32. J Natl Compr Canc Netw. 2005 Nov;3 Suppl 1:S50-3 - PubMed
  33. Thromb Res. 2018 Apr;164 Suppl 1:S112-S118 - PubMed
  34. Haemostasis. 2001;31 Suppl 1:68-9 - PubMed
  35. Blood. 2012 Jan 26;119(4):933-9; quiz 1093 - PubMed
  36. Curr Opin Pulm Med. 1998 Jul;4(4):220-5 - PubMed
  37. Ann Surg Oncol. 2014 Dec;21(13):4232-8 - PubMed
  38. J Thromb Haemost. 2007 Mar;5(3):632-4 - PubMed
  39. Thromb Haemost. 1994 Aug;72(2):186-90 - PubMed
  40. Thromb Haemost. 1991 Mar 4;65(3):251-6 - PubMed
  41. Chest. 2002 Dec;122(6):1933-7 - PubMed
  42. Ann Surg. 2014 Apr;259(4):665-9 - PubMed
  43. Angiology. 1999 Oct;50(10):781-7 - PubMed
  44. BMC Cancer. 2014 Mar 19;14:204 - PubMed
  45. J Clin Oncol. 2020 Feb 10;38(5):496-520 - PubMed
  46. N Engl J Med. 2000 Dec 21;343(25):1846-50 - PubMed
  47. Lancet. 1993 Jan 30;341(8840):259-65 - PubMed
  48. Arch Intern Med. 1993 Jul 12;153(13):1541-6 - PubMed
  49. J Clin Oncol. 2015 Jun 20;33(18):2028-34 - PubMed
  50. Circulation. 1989 Oct;80(4):935-40 - PubMed
  51. Ann Surg. 2014 Jun;259(6):1073-9 - PubMed
  52. BMJ. 2006 Feb 11;332(7537):325-9 - PubMed
  53. J Clin Oncol. 2005 Jun 20;23(18):4057-62 - PubMed
  54. Haemostasis. 1996 May-Jun;26(3):127-39 - PubMed
  55. JAMA. 2015 Aug 18;314(7):677-686 - PubMed
  56. Haemostasis. 1986;16 Suppl 2:30-7 - PubMed
  57. Arch Intern Med. 1999 Oct 25;159(19):2298-304 - PubMed
  58. J Clin Epidemiol. 2013 Sep;66(9):1014-1021.e1 - PubMed
  59. Am J Surg. 1983 Nov;146(5):581-5 - PubMed
  60. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006649 - PubMed
  61. Haematologica. 2015 Jan;100(1):e35-8 - PubMed
  62. Cancer Treat Rev. 2003 Jun;29 Suppl 2:11-3 - PubMed
  63. N Engl J Med. 1999 Sep 9;341(11):793-800 - PubMed
  64. Medicine (Baltimore). 1999 Sep;78(5):285-91 - PubMed
  65. Thromb Res. 2010 Mar;125(3):e65-70 - PubMed
  66. Thromb Haemost. 1992 Jul 6;68(1):14-8 - PubMed
  67. Thromb Res. 2017 Mar;151:89-95 - PubMed
  68. Arch Intern Med. 2000 Mar 27;160(6):809-15 - PubMed
  69. Am J Obstet Gynecol. 1993 Apr;168(4):1146-53; discussion 1153-4 - PubMed
  70. J Clin Oncol. 2000 Sep;18(17):3078-83 - PubMed
  71. Oncologist. 2021 Jan;26(1):e24-e40 - PubMed
  72. J Clin Epidemiol. 2020 Mar;119:126-135 - PubMed
  73. Thromb Haemost. 2015 Jul;114(1):150-7 - PubMed
  74. BMJ. 1994 Jul 30;309(6950):299-304 - PubMed
  75. Eur Radiol. 2002 Nov;12(11):2627-43 - PubMed
  76. Blood Coagul Fibrinolysis. 2011 Dec;22(8):760-2 - PubMed
  77. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003076 - PubMed
  78. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006649 - PubMed
  79. Thromb Haemost. 2003 Aug;90(2):252-9 - PubMed
  80. Br J Haematol. 2013 Feb;160(4):530-7 - PubMed
  81. J Thromb Haemost. 2014 Oct;12(10):1746-9 - PubMed
  82. N Engl J Med. 1996 Mar 14;334(11):682-7 - PubMed
  83. Am J Hematol. 1998 Nov;59(3):260-1 - PubMed
  84. Thromb Haemost. 2009 Apr;101(4):762-9 - PubMed
  85. Thromb Haemost. 1999 Oct;82(4):1222-6 - PubMed
  86. Ann Intern Med. 2001 Feb 6;134(3):191-202 - PubMed
  87. BMC Cancer. 2009 Oct 06;9:355 - PubMed
  88. Thromb Res. 1992 Oct 1;68(1):33-43 - PubMed
  89. BMC Cancer. 2011 Jul 26;11:316 - PubMed
  90. Cochrane Database Syst Rev. 2014 Jun 19;(6):CD006649 - PubMed
  91. Ann Intern Med. 1999 May 18;130(10):800-9 - PubMed
  92. Aust N Z J Obstet Gynaecol. 1998 Feb;38(1):91-2 - PubMed
  93. J Clin Oncol. 2016 Feb 10;34(5):488-94 - PubMed
  94. Am J Surg. 1997 Jul;174(1):1-5 - PubMed
  95. Circulation. 2004 Aug 17;110(7):874-9 - PubMed
  96. Rev Clin Esp. 2002 Aug;202(8):430-4 - PubMed
  97. Thromb Haemost. 2000 May;83(5):652-6 - PubMed
  98. Thromb Haemost. 2017 Jan 5;117(1):57-65 - PubMed
  99. J Urol. 1969 Aug;102(2):240-3 - PubMed
  100. Vasc Med. 2007 May;12(2):123-7 - PubMed
  101. J Thromb Haemost. 2010 Jun;8(6):1223-9 - PubMed
  102. Cochrane Database Syst Rev. 2010 Sep 08;(9):CD001100 - PubMed
  103. Thromb Haemost. 1997 Jul;78(1):126-32 - PubMed
  104. N Engl J Med. 1997 Sep 4;337(10):657-62 - PubMed
  105. N Engl J Med. 1996 Mar 14;334(11):677-81 - PubMed
  106. J Clin Epidemiol. 2017 Jul;87:14-22 - PubMed
  107. Am J Surg. 1970 Oct;120(4):527-30 - PubMed
  108. Ann Intern Med. 2004 Jun 1;140(11):867-73 - PubMed
  109. PLoS One. 2013;8(2):e57132 - PubMed
  110. Thromb Haemost. 1996 Nov;76(5):682-8 - PubMed
  111. N Engl J Med. 2001 Mar 1;344(9):626-31 - PubMed
  112. Arch Intern Med. 2000 Dec 11-25;160(22):3431-6 - PubMed
  113. Blood. 2005 Dec 15;106(13):4027-33 - PubMed
  114. N Engl J Med. 2003 Jul 10;349(2):109-11 - PubMed
  115. N Engl J Med. 1992 Apr 9;326(15):975-82 - PubMed
  116. BMC Cancer. 2013 Jun 13;13:284 - PubMed
  117. Obstet Gynecol. 2001 Dec;98(6):989-95 - PubMed
  118. N Engl J Med. 2003 Oct 30;349(18):1713-21 - PubMed
  119. Blood. 2002 Nov 15;100(10):3484-8 - PubMed
  120. Clin Genitourin Cancer. 2015 Feb;13(1):32-8 - PubMed
  121. Thromb Haemost. 1990 Dec 28;64(4):506-10 - PubMed
  122. Br J Surg. 2005 Oct;92(10):1212-20 - PubMed
  123. Thromb Haemost. 1992 Jun 1;67(6):627-30 - PubMed
  124. J Obstet Gynaecol Res. 2015 Sep;41(9):1440-8 - PubMed
  125. Semin Vasc Med. 2001;1(1):111-22 - PubMed
  126. Arch Intern Med. 2000 Jan 24;160(2):181-8 - PubMed
  127. Cancer. 2008 Oct 1;113(7):1685-94 - PubMed
  128. J Clin Oncol. 2000 Sep;18(17):3065-7 - PubMed
  129. J Intern Med. 1996 Aug;240(2):85-92 - PubMed
  130. Cochrane Database Syst Rev. 2017 Feb 09;2:CD001100 - PubMed
  131. J Clin Oncol. 2011 Mar 10;29(8):986-93 - PubMed
  132. Thromb Haemost. 1999 Aug;82(2):947-52 - PubMed
  133. Thromb Haemost. 1996 Feb;75(2):233-8 - PubMed
  134. J Vasc Surg. 2002 Nov;36(5):917-21 - PubMed
  135. Lancet. 1992 Jun 13;339(8807):1476 - PubMed
  136. N Engl J Med. 1997 Sep 4;337(10):663-9 - PubMed
  137. Cochrane Database Syst Rev. 2018 Jan 24;1:CD006649 - PubMed
  138. J Clin Epidemiol. 2019 Nov;115:55-63 - PubMed
  139. Am J Med. 2006 Dec;119(12):1062-72 - PubMed
  140. N Engl J Med. 2013 Feb 21;368(8):709-18 - PubMed
  141. Arch Intern Med. 2000 Jan 24;160(2):229-36 - PubMed
  142. Ann Intern Med. 1995 Jul 1;123(1):1-9 - PubMed
  143. Haemostasis. 1990;20 Suppl 1:220-3 - PubMed
  144. J Am Coll Cardiol. 2019 Mar 26;73(11):1336-1349 - PubMed
  145. Neurosurgery. 1998 Nov;43(5):1074-81 - PubMed
  146. J Clin Oncol. 2005 Jun 20;23(18):4063-9 - PubMed
  147. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  148. BMC Cancer. 2008 Dec 05;8:361 - PubMed

Publication Types